The MiR-328-3p-CPT1A-FAO pathway is crucial for the metastasis of breast cancer, and miR-328-3p upregulation can be used for reducing metastasis in breast cancer patients (Zeng et al., 2022)
Today, AOD-9604 remains a topic of scientific interest, not as an approved therapy, but as a case study in how translational challenges can derail promising preclinical results
J.XavierR
The drug is indicated for chronic weight management in patients with a body mass index (BMI) of 27 kg/m2 or greater who have at least one weight-related ailment or in patients with a BMI of 30 kg/m2 or greater
This can cause symptoms such as poor growth, developmental delays, irritability, and failure to thrive in severe cases [*]
first posted on 03/02/2021, for the L-serine medication designated as Speragen (AST-001)